Get the Stockscreener App
18.39
2.37%
-0.425
Cartesian Therapeutics Inc stock is traded at $18.39, with a volume of 45,376.
It is down -2.37% in the last 24 hours and up +7.02% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
See More
Previous Close:
$18.81
Open:
$18.81
24h Volume:
45,376
Relative Volume:
0.39
Market Cap:
$483.89M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.3692
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-4.89%
1M Performance:
+7.02%
6M Performance:
+29.24%
1Y Performance:
-4.84%
1-Day Range:
$17.69
$19.03
1-Week Range:
$17.69
$20.00
52-Week Range:
$11.66
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
18.49 | 483.89M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.01 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.71 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World
Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times
Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com
FDA Grants Special Protocol Assessment for Cartesian's Myasthenia Gravis Treatment - StockTitan
Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World
Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha
Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat
Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks
Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Myasthenia Gravis Market Poised for Significant Growth from - openPR
Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat
Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com
Cartesian Therapeutics Awards Stock Options to New Employees in Retention Move - StockTitan
Barclays PLC Purchases 7,849 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33% - Simply Wall St
Critical Review: Cartesian Therapeutics (RNAC) vs. The Competition - Defense World
State Street Corp Has $2.54 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) Trading 7.2% HigherStill a Buy? - MarketBeat
Cartesian Therapeutics ATM - Leerink Partners
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - Defense World
Cartesian therapeutics director Timothy Springer buys $965k in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics director Timothy Springer buys $965k in stock - Investing.com
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cartesian Therapeutics Inc Stock (RNAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Jan 14 '25 |
Buy |
18.00 |
4,022 |
72,396 |
8,531,462 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 10 '25 |
Option Exercise |
3.23 |
9,000 |
29,070 |
62,490 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 06 '25 |
Sale |
16.83 |
2,458 |
41,374 |
62,258 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 03 '25 |
Sale |
16.72 |
2,417 |
40,417 |
64,716 |
| Miljkovic Milos | Chief Medical Officer |
Jan 06 '25 |
Sale |
16.83 |
948 |
15,957 |
35,393 |
| Miljkovic Milos | Chief Medical Officer |
Jan 03 '25 |
Sale |
16.72 |
932 |
15,585 |
36,341 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 06 '25 |
Sale |
16.83 |
1,286 |
21,646 |
53,490 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 03 '25 |
Sale |
16.72 |
1,264 |
21,136 |
54,776 |
| English Emily | Chief Operations Officer |
Jan 06 '25 |
Sale |
16.83 |
906 |
15,250 |
40,226 |
| English Emily | Chief Operations Officer |
Jan 03 '25 |
Sale |
16.72 |
891 |
14,899 |
41,132 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):